Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease

Annals of Internal Medicine

Volumn 133, Issue 4, 2000, Pages 275-279

  Ratanatharathorn, V ^a   Carson, E ^a   Reynolds, C ^a   Ayash, L J ^a   Levine, J ^a   Yanik, G ^a   Silver, S M ^a   Ferrara, J L M ^a   Uberti, J P ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0034662901     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-4-200008150-00011     Document Type: Article

References (20)

1. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease
2. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
3. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
4. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease
5. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
6. Graft-v-host disease is associated with autoimmune-like thrombocytopenia
7. Autoantibodies in chronic GVHD: High prevalence of antinucleolar antibodies
8. Use of rituximab, the new FDA-approved antibody
9. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
10. Tacrolimus: A new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation
11. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura
12. Lymphocyte dysfunction in chronic graft-versus-host disease
13. Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation
14. Monoclonal and oligoclonal gammopathy after bone marrow transplantation
15. Reconstitution of B cell immunity following bone marrow transplantation
16. Autoimmune diseases induced by graft-vs-host disease
17. The immune system: Effector and target of graft-vs.-host disease
18. TH2 cells in systemic autoimmunity: Insights from allogeneic diseases and chemically-induced autoimmunity
19. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity
20. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes